Cempra, Inc. (CEMP)
(Delayed Data from NSDQ)
$2.33 USD
+0.03 (1.09%)
Updated Nov 3, 2017 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Melinta Therapeutics, Inc. [CEMP]
Reports for Purchase
Showing records 21 - 40 ( 89 total )
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
In 7-6 Vote, AdCom Panel Recommends Solithromycin Approval
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
AdCom Briefing Documents Highlight Hepatic Risks
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
Q3 Reported; Mfr''g Delay Likely to Push YE Approval to Mid-?17
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
Positive Interim Results With Solithera in NASH
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
2Q''16 In Line; $75M Raised Via ATM Extends Cash Runway
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
Company: Melinta Therapeutics, Inc.
Industry: Medical - Drugs
Re-Initiation: Catching an Opportunity in Pneumonia; Buy Rating and $37 PT
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M